Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): A phase II study

British Journal of Haematology

Volumn 149, Issue 5, 2010, Pages 706-710

  Scott, Bart L ^a,b   Ramakrishnan, Aravind ^a,b   Fosdal, Mark ^a   Storer, Barry ^a,b   Becker, Pamela ^a   Petersdorf, Steve ^a,b   Deeg, H Joachim ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Anti thymocyte globulin; Etanercept; Haematopoiesis; Immunosuppressives; Myelodysplastic syndrome

Indexed keywords

ETANERCEPT; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; HYPOTENSION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; REMISSION; SERUM SICKNESS; SURVIVAL RATE; THROMBOCYTE TRANSFUSION; URTICARIA;

AGED; AGED, 80 AND OVER; ANTILYMPHOCYTE SERUM; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952602288     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08145.x     Document Type: Article

References (23)

1. Cheson, B.D., Greenberg, P.L., Bennett, J.M., Lowenberg, B., Wijermans, P., Nimer, S.D., Pinto, A., Beran, M., de Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Gore, S.D., Schiffer, C.A. Kantarjian, H. (2006) Clinical applications and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood, 108, 419 425.
2. Deeg, H.J., Beckham, C., Loken, M.R., Bryant, E., Lesnikova, M., Shulman, H.M. Gooley, T. (2000) Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leukemia and Lymphoma, 37, 405 414.
3. Deeg, H.J., Gotlib, J., Beckham, C., Dugan, K., Holmberg, L., Schubert, M., Appelbaum, F. Greenberg, P. (2002) Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia, 16, 162 164.
4. Deeg, H.J., Jiang, P.Y.Z., Holmberg, L.A., Scott, B., Petersdorf, E.W. Appelbaum, F.R. (2004) Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leukemia Research, 28, 1177 1180.
5. Gersuk, G.M., Beckham, C., Loken, M.R., Kiener, P., Anderson, J.E., Farrand, A., Troutt, A.B., Ledbetter, J.A. Deeg, H.J. (1998) A role for tumor necrosis factor-α, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. British Journal of Haematology, 103, 176 188.
6. Killick, S.B., Mufti, G., Cavenagh, J.D., Mijovic, A., Peacock, J.L., Gordon-Smith, E.C., Bowen, D.T. Marsh, J.C. (2003) A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. British Journal of Haematology, 120, 679 684.
7. Kitagawa, M., Saito, I., Kuwata, T., Yoshida, S., Yamaguchi, S., Takahashi, M., Tanizawa, T., Kamiyama, R. Hirokawa, K. (1997) Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia, 11, 2049 2054.
8. Kochenderfer, J.N., Kobayashi, S., Wieder, E.D., Su, C. Molldrem, J.J. (2002) Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood, 100, 3639 3645.
9. Lim, Z.Y., Killick, S., Germing, U., Cavenagh, J., Culligan, D., Bacigalupo, A., Marsh, J. Mufti, G.J. (2007) Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia, 21, 1436 1441.
10. Maciejewski, J.P., Risitano, A.M., Sloand, E.M., Wisch, L., Geller, N., Barrett, J.A., Young, N.S. Ristiano, A.M. (2002) A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome (erratum appears in Br J Haematol 2002 Jun;117(4):1002 Note: Ristiano Antonio M [corrected to Risitano Antonio M]). British Journal of Haematology, 117, 119 126.
11. Molldrem, J.J., Caples, M., Mavroudis, D., Plante, M., Young, N.S. Barrett, A.J. (1997) Antithymocyte globulin for patients with myelodysplastic syndrome. British Journal of Haematology, 99, 699 705.
12. Molldrem, J.J., Jiang, Y.Z., Stetler-Stevenson, M., Mavroudis, D., Hensel, N. Barrett, A.J. (1998) Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. British Journal of Haematology, 102, 1314 1322.
13. Molldrem, J.J., Leifer, E., Bahceci, E., Saunthararajah, Y., Rivera, M., Dunbar, C., Liu, J., Nakamura, R., Young, N.S. Barrett, A.J. (2002) Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndrome [summary for patients in Ann Intern Med. 2002 Aug 6;137(3):I-27]. Annals of Internal Medicine, 137, 156 163.
14. Rosenfeld, C. Bedell, C. (2002) Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome. Leukemia Research, 26, 721 724.
15. Saunthararajah, Y., Nakamura, R., Nam, J.M., Robyn, J., Loberiza, F., Maciejewski, J.P., Simonis, T., Molldrem, J., Young, N.S. Barrett, A.J. (2002) HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood, 100, 1570 1574.
16. Saunthararajah, Y., Nakamura, R., Wesley, R., Wang, Q.J. Barrett, A.J. (2003) A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood, 102, 3025 3027.
17. Sawanobori, M., Yamaguchi, S., Hasegawa, M., Inoue, M., Suzuki, K., Kamiyama, R., Hirokawa, K. Kitagawa, M. (2003) Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leukemia Research, 27, 583 591.
18. Scott, B.L., Wells, D.A., Loken, M.R., Myerson, D., Leisenring, W.M. Deeg, H.J. (2008) Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood, 112, 2681 2686.
19. Sloand, E.M., Wu, C.O., Greenberg, P., Young, N. Barrett, J. (2008) Factors affecting response and survival in patients with myelodysplasia treated with immunosupporessive therapy. Journal of Clinical Oncology, 26, 2505 2511.
20. Stadler, M., Germing, U., Kliche, K.O., Josten, K.M., Kuse, R., Hofmann, W.K., Schrezenmeier, H., Novotny, J., Anders, O., Eimermacher, H., Verbeek, W., Kreipe, H.H., Heimpel, H., Aul, C. Ganser, A. (2004) A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia, 18, 460 465.
21. Steensma, D.P., Dispenzieri, A., Moore, S.B., Schroeder, G. Tefferi, A. (2003) Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood, 101, 2156 2158.
22. Vardiman, J.W., Harris, N.L. Brunning, R.D. (2002) The World Health Organization (WHO) classification of the myeloid neoplasms (Review). Blood, 100, 2292 2302.
23. Yazji, S., Giles, F.J., Tsimberidou, A.M., Estey, E.H., Kantarjian, H.M., O'Brien, S.A. Kurzrock, R. (2003) Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia, 17, 2101 2106.